Substituted benzamides and their uses
Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.
1. A compound selected from the group consisting of
4-(5-methyl-4-((piperazin-1-ylsulfonyl)methyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
4-(5-methyl-4-((4-methylpiperazin-1-ylsulfonyl)methyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
4-(4-((4-isobutylpiperazin-1-ylsulfonyl)methyl)-5-methyloxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
4-(4-((4-tert-butylpiperazin-1-ylsulfonyl)methyl)-5-methyloxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
4-(4-((4-cyclopropylpiperazin-1-ylsulfonyl)methyl)-5-methyloxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
4-(5-methyl-4-((4-(2,2,2-trifluoroethyl)piperazin-1-ylsulfonyl)methyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
4-(5-methyl-4-(morpholinosulfonylmethyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
4-(4-((4-isopropylpiperazin-1-ylsulfonyl)methyl)-5-methyloxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
4-(5-methyl-4-(((4-neopentylpiperazin-1-yl)sulfonyl)methyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
4-(4-(((4-ethylpiperazin-1-yl)sulfonyl)methyl)-5-methyloxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
4-(4-(((4-cyclobutylpiperazin-1-yl)sulfonyl)methyl)-5-methyloxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide, and
4-(5-methyl-4-((thiomorpholinosulfonyl)methyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide,
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein the compound is 4-(5-methyl-4-((piperazin-1-ylsulfonyl)methyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide.
3. The compound of claim 1 wherein the compound is 4-(5-methyl-4-((4-methylpiperazin-1-ylsulfonyl)methyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide.
4. The compound of claim 1 wherein the compound is 4-(4-((4-isobutylpiperazin-1-ylsulfonyl)methyl)-5-methyloxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide.
5. The compound of claim 1 wherein the compound is 4-(5-methyl-4-(morpholinosulfonylmethyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide.
6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
7. A method for treating renal carcinoma mediated by HIF-1α and/or HIF-2α, the method comprising administering to a subject a compound as defined in claim 1 .